Abiopharma

🔍 SYLEBRA CAPITAL LLC (Director)

Company: IMPINJ INC (PI)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Sold 11,602 shares of Common Stock at $128.8684 per share (Direct)
  Date: 2026-06-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 876,453.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 35,877 shares of Common Stock at $122.5003 per share (Direct)
  Date: 2026-06-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 840,576.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: (1) Sylebra Capital LLC (Sylebra US) and Sylebra Capital Limited (Sylebra HK) are the investment sub-advisers to Sylebra Capital Partners Master Fund, Ltd. (SCPMF), Sylebra Capital Menlo Master Fund (MENLO MF), and other advisory clients. Sylebra Capital Management (Sylebra Cayman) is the investment manager and parent of Sylebra HK. Sylebra Cayman owns 100% of the shares of Sylebra HK and Daniel Patrick Gibson (Gibson) owns more than 100% of the Class A shares of Sylebra Cayman and 100% of the share capital of Sylebra US. Gibson is a founder and Chief Investment Officer of Sylebra Cayman. In such capacities, Sylebra US, Sylebra HK, Sylebra Cayman and Gibson may be deemed to share voting and dispositive power over the shares of common stock of the Issuer held by SCP MF, MENLO MF, and other advisory clients.
• F2: (2) These securities are held by SCP MF, MENLO MF, and other advisory clients. Gibson is a member of the board of directors of the Issuer. Sylebra US, Sylebra HK, Sylebra Cayman and Gibson disclaim beneficial ownership of these securities, and this report shall not be deemed an admission that Sylebra US, Sylebra HK, Sylebra Cayman and Gibson are the beneficial owners of such securities, except to the extent of their pecuniary interest, if any, therein.